



Hyaluxelle®

Patient Information Leaflet

THE ART OF FEELING

LET INNOVATION AWAKEN WHAT THE BODY HAS SILENCED

Next generation hyaluronic acid designed to relieve vulvovaginal symptoms associated with genitourinary syndrome of menopause (GSM)



Caring Innovation

This leaflet is for patients and provides information about a Hyaluxelle procedure to treat genital and sexual symptoms of genitourinary syndrome of menopause (GSM).

What is GSM?

GSM is a collection of symptoms affecting the female pelvic and reproductive organs caused by low oestrogen. This may be caused by natural menopause, premature ovarian insufficiency or medical treatments (such as surgical removal of ovaries, chemotherapy and radiotherapy treatments). Low oestrogen contributes to thinning of the vaginal walls, reduction in tissue elasticity and reduction in natural lubrication^{1,2}.

What are the symptoms of GSM?

Symptoms include:

1. Vaginal dryness (sexual dysfunction)
2. Pain during sexual intercourse (sexual dysfunction)
3. Burning (genital symptoms)
4. Itching (genital symptoms)
5. Altered vaginal pH and vaginal infections (thrush, bacterial vaginosis)
6. Urinary urgency (urinary)
7. Urinary frequency (urinary)
8. Urinary tract infections (urinary)^{1,2}

How common is GSM?

Whilst up to 70% of menopausal women will experience symptoms of GSM, only 7% receive treatment, meaning women are suffering in silence¹. Symptoms are often attributed to normal ageing and therefore left unreported and untreated. Symptoms often lead to reduced sexual activity, which impacts quality of life for both women and their partners².

How is it diagnosed?


Your clinician may ask you questions about your symptoms, lifestyle and sexual history and conduct a physical examination. Laboratory tests are not generally needed to make a GSM diagnosis. GSM symptoms may be attributed to other conditions such as vaginal or urinary infection, so it is crucial your clinician obtains a thorough history and examination to distinguish GSM from other conditions¹.

How can Hyaluxelle help?

Designed to be compatible with our body's natural hyaluronic acid⁷, Hyaluxelle restores the natural environment of vulvovaginal tissues, by:

1. Increasing tissue thickness,^{3,4}
2. Increasing tissue hydration,⁷
3. Reducing inflammatory cells^{3,4}
4. Improving blood flow to the area^{3,4}

This may lead to reduction in painful genital symptoms such as burning, itching and discomfort, reduced pain during sexual penetration, improved sexual function and a better quality of life for women⁵.




What is Hyaluxelle?

Hyaluxelle is a high and low molecular weight hyaluronic acid injection designed to stimulate atrophic tissues. It is a medical device licensed to treat vaginal dryness, pain during sexual intercourse, genital burning and itching (non-infectious) related to vulvovaginal atrophy⁷.

Where is the injection administered?

All woman's vaginal tissues are individual. Your clinician will decide based on your history and examination where to administer the injection to treat your specific symptoms. The injections are delivered into the vulvovaginal tissues using a very small needle. Your clinician may ask you to apply anaesthetic cream to the area prior to the injections. Only trained clinicians can administer Hyaluxelle injections.



How many injections of Hyaluxelle will I need?

There are two treatments, spaced 30 days apart⁷.

Are there any risks/side effects?

Hyaluxelle is well tolerated with no known long-term risks or interactions^{5,7}. Injections should be performed on healthy skin. Hyaluxelle may cause temporary local side effects including⁷:

- Sensation of heat
- Slight bruising
- Redness
- Itching at injection site
- Temporary pain or swelling at injection site
- Oedema
- Ecchymosis
- Erythema
- Bruising
- Temporary pain and/or swelling

These side effects can be relieved by applying ice on the treated area. They generally disappear after a short period of time.

If you experience undesirable effects during or after your treatment, you must inform your clinician.

You should not have Hyaluxelle if:

- Are pregnant or breast feeding
- Have an autoimmune disease
- Have a collagen disorder (for example Ehler's Danlos)⁷
- Have known hypersensitivity or allergies to the components or product

What should I avoid after the injection?

- You should avoid a sauna or a Turkish bath and sports such as cycling or horse riding and sexual intercourse in the 3 days following the treatment
- You should avoid sun exposure, or exposure to UV rays for 3-5 days after injection⁷

GSM over time

It is important to consider your symptoms and discuss these with your health care professional when deciding which treatment is best for you. GSM unlike other menopause symptoms may not improve spontaneously but usually progresses over time¹.

Where can I get more information about Hyaluxelle?
Scan the QR code or visit: www.ibsaurogyn.com



IBSA VITAMINS:

Maintaining your levels of important supplements is important to recovery and can be done through a balanced diet. But if you need additional support, IBSAs innovative technology makes taking supplements easy.

Taking vitamins daily is easier when you enjoy them:

Practical

Thin films that melt on your tongue quickly without the need for water.

Portable

Small and lightweight films ready to take anytime, anywhere.

Precise

Consistent vitamin dosages in each film.



Our convenient, thin-film vitamins melt on your tongue quickly without the need for water.

Scan the QR code or visit www.ibsacare.co.uk for more information



References

1. Newson, L. Stillwell, S. Ball, S. (2024). Position statement for Management of Genitourinary syndrome of the menopause. British Society of sexual medicine. Position Statement for Management of GSM
2. Briggs, P. (2025) British Menopause Society Consensus Statement Genitourinary Syndrome of Menopause. Accessed online 09-NEW-BMS-ConsensusStatement-Genitourinary-Syndrome-of-Menopause-GSM-NOV2025-B.pdf
3. Garavaglia, E. Dell'Antonio, G. Bellani, E. Tateo, A. (2023) Hyaluronic acid used in the female genital area: technique proposal.
4. Stellavato A, Corsuto L, D'Agostino A, La Gatta A, Diana P, Bernini P, De Rosa M, Schiraldi C. (2016) Hyaluronan Hybrid Cooperative Complexes as a Novel Frontier for Cellular Bioprocesses Re-Activation. PLoS One. Oct 10;11(10):e0163510. doi: 10.1371/journal.pone.0163510.
5. Mohammed GF, Al-Dhubaibi MS.(2024). Hybrid high- and low-molecular weight chains of hyaluronan is an effective modality treatment for increasing female sexual satisfaction: An interventional, randomized-control parallel study. Health Sci Rep. Feb 28;6(3):e870. doi: 10.1002/hsr2.870. PMID: 36865530; PMCID: PMC9972869.
6. Garavaglia E, Sala C, Busato M, Bellia G, Tamburlin N, Massirone A. First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome. Med Devices (Auckl). 2020 Dec 4;13:399-410. doi: 10.2147/MDER.S275966. PMID: 33304110; PMCID: PMC7723235.
7. Hyaluxelle Instructions for use



To access the Hyaluxelle IFU, please scan the QR code

IBSA UK

Sullivan House, 4-6 Colonial Business Park,
Colonial Way, Watford WD24 4PR, UK

Phone: +44 1923 233 466

Job bag code: UKHYE00047 Date of preparation: February 2026



Caring Innovation